Quizartinib is primarily used in the treatment of acute myeloid leukemia (AML), particularly for patients with FLT3-ITD mutations. It functions as a potent and selective FLT3 inhibitor, targeting the mutated FLT3 receptor tyrosine kinase, which is often associated with aggressive disease progression. By inhibiting this mutation, quizartinib helps to slow down or stop the growth of cancer cells. It is typically administered to patients who have relapsed or are refractory to other treatments, offering a targeted therapeutic option. Clinical trials have demonstrated its efficacy in improving overall survival and remission rates in this specific patient population. Additionally, it is sometimes used in combination with other chemotherapy agents to enhance its effectiveness.